OTCPK:IMMV.F

Stock Analysis Report

Executive Summary

Immunovia AB (publ), a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Immunovia's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

IMMV.F

1.7%

US Medical Equipment

2.3%

US Market


1 Year Return

n/a

IMMV.F

10.1%

US Medical Equipment

5.6%

US Market

Return vs Industry: Insufficient data to determine how IMMV.F performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how IMMV.F performed against the US Market.


Shareholder returns

IMMV.FIndustryMarket
7 Day0%1.7%2.3%
30 Day0%-1.7%-1.0%
90 Day-3.5%-1.7%-0.7%
1 Yearn/a11.0%10.1%7.9%5.6%
3 Yearn/a70.4%65.2%45.6%36.3%
5 Yearn/a128.5%103.2%65.8%47.6%

Price Volatility Vs. Market

How volatile is Immunovia's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Immunovia undervalued compared to its fair value and its price relative to the market?

7.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate IMMV.F's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate IMMV.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IMMV.F is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: IMMV.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate IMMV.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IMMV.F is overvalued based on its PB Ratio (7.2x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Immunovia forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

23.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immunovia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Immunovia performed over the past 5 years?

-59.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: IMMV.F is unprofitable, and losses have increased over the past 5 years at a rate of -59.6% per year.

Accelerating Growth: Unable to compare IMMV.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMMV.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: IMMV.F has a negative Return on Equity (-24.53%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: IMMV.F is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: IMMV.F is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Immunovia's financial position?


Financial Position Analysis

Short Term Liabilities: IMMV.F's short term assets (SEK332.7M) exceeds its short term liabilities (SEK27.3M)

Long Term Liabilities: IMMV.F's short term assets (332.7M) exceeds its long term liabilities (29.2M)


Debt to Equity History and Analysis

Debt Level: IMMV.F is debt free.

Reducing Debt: IMMV.F has not had any debt for past 5 years.


Balance Sheet

Inventory Level: IMMV.F has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if IMMV.F's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMMV.F has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IMMV.F has sufficient cash runway for 2.230081 years if free cash flow continues to reduce at historical rates of -44.1% each year.


Next Steps

Dividend

What is Immunovia's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate IMMV.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IMMV.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if IMMV.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMMV.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IMMV.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Immunovia's salary, the management and board of directors tenure and is there insider trading?

5.8yrs

Average management tenure


CEO

Mats Grahn (57yo)

6.8yrs

Tenure

kr3,230,759

Compensation

Mr. Mats Grahn has been Chief Executive Officer of Immunovia AB (publ) since 2013. Mr. Grahn served as the Vice President of Product Management of Protein Separations at GE Healthcare Ltd. He has more than ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Mats's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Mats's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

5.8yrs

Average Tenure

55yo

Average Age

Experienced Management: IMMV.F's management team is seasoned and experienced (5.8 years average tenure).


Board Age and Tenure

3.0yrs

Average Tenure

60yo

Average Age

Experienced Board: IMMV.F's board of directors are considered experienced (3 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Rolf Ehrnström (66yo)

    Chief Scientific Officer

    • Tenure: 6.8yrs
  • Thomas King

    Medical Director

    • Tenure: 0yrs
  • Mats Grahn (57yo)

    Chief Executive Officer

    • Tenure: 6.8yrs
    • Compensation: kr3.23m
  • Laura Chirica (51yo)

    Chief Commercial Officer

    • Tenure: 4.8yrs
  • Hans Liljenborg (61yo)

    Chief Financial Officer

    • Tenure: 6.8yrs
  • Linda Mellby (40yo)

    Vice President of Research & Development

    • Tenure: 5.8yrs
  • Christer Wingren (53yo)

    Chief Technology Officer

    • Tenure: 0yrs
  • Lotta Blomgren (59yo)

    Operations Director

    • Tenure: 3.1yrs
  • Henrik Winther (53yo)

    Senior Vice President of Business Development

    • Tenure: 2.4yrs
  • Julie Silber

    Director of Investor Relations

    • Tenure: 0yrs

Board Members

  • Carl Arne Borrebäck (71yo)

    Chairman of the Board of Directors

    • Tenure: 12.8yrs
    • Compensation: kr360.00k
  • Hans Johansson (65yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: kr153.33k
  • Margaret Tempero

    Member of Scientific Advisory Board

    • Tenure: 3.3yrs
  • Ann-Christine Sundell (55yo)

    Director

    • Tenure: 2.8yrs
    • Compensation: kr166.67k
  • Christofer Sjögren (53yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: kr100.00k
  • Diane Simeone

    Member of Scientific Advisory Board

    • Tenure: 3.3yrs
  • Marco Del Chiaro

    Member of Advisory Board

    • Tenure: 3.5yrs
  • Aldo Scarpa

    Member of Scientific Advisory Board

    • Tenure: 3.3yrs
  • Stephen Pereira

    Member of Scientific Advisory Board

    • Tenure: 2.3yrs
  • Mimmi Ekberg (60yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: kr100.00k

Company Information

Immunovia AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Immunovia AB (publ)
  • Ticker: IMMV.F
  • Exchange: OTCPK
  • Founded: 2007
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr2.917b
  • Listing Market Cap: kr300.286m
  • Shares outstanding: 19.65m
  • Website: https://www.immunovia.com

Number of Employees


Location

  • Immunovia AB (publ)
  • Medicon Village
  • Scheelevägen 2
  • Lund
  • Skåne County
  • 223 81
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMMNOVOM (OMX Nordic Exchange Stockholm)YesShare CapitalSESEKDec 2015
0G8XLSE (London Stock Exchange)YesShare CapitalGBSEKDec 2015
IMMV.FOTCPK (Pink Sheets LLC)YesShare CapitalUSUSDDec 2015
IMMNOSBATS-CHIXE (BATS 'Chi-X Europe')YesShare CapitalGBSEKDec 2015

Biography

Immunovia AB (publ), a molecular diagnostics company, develops and commercializes diagnostic tools for cancer and autoimmune diseases in Sweden and internationally. The company offers IMMray PanCan-d, a bl ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 00:53
End of Day Share Price2019/07/26 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.